Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ankit Gupta [https://www.linkedin.com/in/reachankit/], CEO at Tenshi Kaizen [https://insta-pill.com/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ankit, covering: * His accidental journey into pharma, and then pharma manufacturing * How his exposure to the pharma value chain via consulting led to numerous roles in the sector, including a critical one at Strides Pharma Sciences Limited [https://strides.com/] and other group companies held by the founders * The honour of being appointed CEO at Tenshi, and building out InstaPill(R) - its proprietary oral drug delivery technology - from incubation to growth * Why India is poised for growth now that it's leading the 'D' as well as the 'M' of CDMO * The lay of the land in India's biopharma and pharma ecosystem Ankit Gupta is a seasoned finance and strategy leader with close to 15 years of experience in the pharmaceutical and biotechnology sectors. At Tenshi Kaizen, he leads the development and global expansion of innovative pharmaceutical technology platforms, including the flagship InstaPill. He also serves as the Chief Corporate Strategy & Development Officer across all group entities promoted by the founders. Ankit is known for his expertise in corporate strategy, growth acceleration, and business transformation. In his prior role as Vice President – Strategy and Corporate Development at Gland Pharma Limited and Strides Group, he played a pivotal role in long-range planning, financial forecasting, and strategic initiatives that contributed to the Strides Group turnaround in the financial year 2022-2023. He brings deep experience in both organic and inorganic growth, asset optimization, and risk management. A gold medalist in MBA (Finance), Ankit also holds global certifications in corporate finance, private equity, valuations, business leadership, and strategy, bringing a rare blend of financial precision and strategic foresight to the group’s leadership. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space.  We’d also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adam Sherlock [https://www.linkedin.com/in/adamsherlock65/], CEO at Qinecsa. [https://qinecsa.com/] Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering: * How he developed his professional CEO skills over the years to complement is entrepreneurial spirit * The combination of micro and macro factors that help determine when the right time is to go to market, and sell * The importance of your gut instinct when assessing M&A targets... and painting a picture of why the world is a better place when together * Several attempts at failing to retire... and being tempted back into another pharma services CEO role * How R&D services will be impacted by AI, and why we all need to be eating our own lunch Adam is a serial entrepreneur and executive leader with nearly 40 years of experience in the international life sciences industry, particularly in bio/pharma, IVD, and medical device sectors. A scientist by training, he has led successful growth and M&A efforts, creating exceptional value in four private equity-backed businesses over the past decade.  Adam is also a sought-after NED, Chair, and independent advisor. Currently, he serves as CEO of Qinecsa, a global provider of pharmacovigilance technology and services. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com [http://boracdmo.com/]) and Charles River (www.criver.com [http://www.criver.com/]), and supported by ramarketing [https://www.ramarketingpr.com/].

In this special episode of Molecule to Market, recorded at this year’s CDMO Live in Rotterdam, industry leaders come together to assess the evolving state of the contract development and manufacturing sector. Raman is the panel moderator, joined by:  * Gil Roth [https://www.linkedin.com/in/gil-roth-93a6711/] - PBOA [https://pharma-bio.org/] * Dr. Jim Li [https://www.linkedin.com/in/jim-li-134a6419/] - BioDuro Sundia [https://www.bioduro.com/] * Kaan-Fabian Kekec [https://www.linkedin.com/in/kaan-fabian-kekec-3b799632/] - Simon-Kucher [https://www.simon-kucher.com/en] They unpack cautious optimism in the face of lingering market uncertainties and geopolitical tension, you’ll hear: * How CDMOs are adapting to early-stage funding strain and evolving pricing models * The impact of rising interest rates, tariffs, and global trade policy on pharma outsourcing * Capacity and talent constraints facing CDMOs in new therapeutic modalities * Why integrated models and scenario planning are key to future-proofing operations This episode offers timely insight into the challenges and opportunities shaping the next phase of growth for CDMOs worldwide. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hella Kohlhof [https://www.linkedin.com/in/hella-kohlhof-4672004b/], CSO at Immunic. [https://imux.com/] Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hella, covering: * How the 'waste of two molecules' led to the spin-out creation of Immunic Therapeutics. * The perfect blend of a founding team willing to split responsibility, learn and have a go. * Ending up as a Nasdaq-listed company via a reverse merger... and all the new challenges that came with it. * Immunic's divide-and-conquer global outsourcing strategy, while retaining tight control. * Examples of how geopolitical issues have impacted a biotech's growth. Hella leads the Immunic's scientific strategy, including mode of action research, preclinical studies, and biomarker development. Dr. Kohlhof brings deep expertise in immunology, oncology, and drug development, with previous roles at 4SC AG [https://www.4sc.com/], where she led preclinical and clinical projects. She holds a doctorate in biology from Ludwig Maximilians University of Munich [https://www.lmu.de/en/] and completed her postdoc at the Helmholtz Centre [https://www.helmholtz.de/en/about-us/helmholtz-centers/], focusing on B cell development. She holds several patents, has co-authored numerous publications, and is a regular speaker at scientific and industry events. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing [https://www.ramarketingpr.com/], an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Showalter [https://www.linkedin.com/in/tim-showalter-08616518/], Radiation Oncologist, Founder and Chief Medical Officer at ArteraAI [https://artera.ai/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering: * The attraction of radiation oncology at med school and his fascination with clinical trials * His frustration with tools for cervical cancer patients led to the creation of a medical device company * How his bootstrapped side project ended in an exit... but why that was inspiring and motivational to move on to the next thing * The proud experience of using his own product (BrachyGel [https://cqmedical.com/Products/radiotherapy/symphony/BrachyGel]) on cancer patients in the clinic, years after coming up with the idea * How ArteraAI's technology is positively disrupting the prostate cancer space, as well as its potential to scale and expand into other disease areas   Tim Showalter, MD, MPH, is a radiation oncologist and cancer researcher who serves as Chief Medical Officer at Artera, where he leads research and medical strategy. Artera is working to improve cancer care by developing AI-enabled prognostic and predictive tests. The ArteraAI Prostate Test is the first of its kind to be recommended by national clinical guidelines for routine use. Tim maintains a part-time clinical practice at the University of Virginia [https://www.virginia.edu/], remaining connected to patient care, research and education. He is the founder of Advaray [https://www.advaray.com/]and inventor of BrachyGel, a novel hydrogel-based medical device for cervical cancer radiation therapy, which is manufactured and marketed by CQ Medical [https://cqmedical.com/]. Tim serves on the board of CQ Medical and cohosts a podcast, HealthTech Remedy to explore the intricacies of innovative health technology companies. Tim is a noted speaker and advisor to start-up companies.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, [https://ramarketingpr.com/] an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.